Gene therapy shows promise in the management of inherited peripheral neuropathy and the complex array of symptoms that patients experience. Gene therapy holds promise in the management of peripheral neuropathies and in significant improvement of quality of life for patients.
Using a constructed ANN model, researchers sought to predict the long-term outcomes of microvascular decompression surgery and the factors that influence prognosis in patients with trigeminal neuralgia.
Presenting at the 2022 AAN Annual Meeting, researchers evaluated the safety and efficacy of vutrisiran using data from HELIOS-A, an ongoing, 18-month, phase 3 trial.
